π
|
EBV PCR in the Diagnosis and Monitoring of Posttransplant Lymphoproliferative Disorder: Results of a TwoβArm Prospective Trial
15 auth.
D. Tsai,
L. Douglas,
C. Andreadis,
D. Vogl,
S. Arnoldi,
R. Kotloff,
J. Svoboda,
Roy D. Bloom,
K. Olthoff,
S. C. Brozena,
...
S. Schuster,
E. Stadtmauer,
Erle S Robertson,
Mariusz A. Wasik,
V. Ahya
|
7 |
2008 |
7 π
|
π
|
T-cell Lymphoma and Secondary Primary Malignancy Risk After Commercial CAR T-cell Therapy.
33 auth.
G. Ghilardi,
J. Fraietta,
J. Gerson,
V. V. Van Deerlin,
Jennifer J D Morrissette,
Gabriel C Caponetti,
L. Paruzzo,
Jaryse Harris,
E. Chong,
Sandra P Susanibar Adaniya,
J. Svoboda,
S. Nasta,
O. Ugwuanyi,
D. Landsburg,
E. Fardella,
...
A. Waxman,
E. Chong,
Vrutti Patel,
R. Pajarillo,
I. Kulikovskaya,
David B. Lieberman,
Adam D. Cohen,
Bruce L. Levine,
E. Stadtmauer,
N. Frey,
D. Vogl,
Elizabeth O Hexner,
Stefan K. Barta,
David L. Porter,
A. Garfall,
S. Schuster,
Carl H. June,
M. Ruella
|
6 |
2024 |
6 π
|
π’
|
Sequential Anti-CD19 Directed Chimeric Antigen Receptor Modified T-Cell Therapy (CART19) and PD-1 Blockade with Pembrolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
12 auth.
E. Chong,
J. Svoboda,
Sunita Dwivedy Nasta,
D. Landsburg,
N. Winchell,
E. Napier,
...
A. Mato,
J. Melenhorst,
M. Ruella,
S. Lacey,
Carl H. June,
S. Schuster
|
6 |
2018 |
6 π’
|
π
|
Bridging Radiation Therapy Prior to Commercial Chimeric Antigen Receptor T-Cell Therapy for relapsed/refractory aggressive B-cell lymphoma.
20 auth.
C. Wright,
M. Lariviere,
J. Baron,
C. Uche,
Ying Xiao,
W. Arscott,
E. Anstadt,
A. Barsky,
David Miller,
M. Larose,
...
D. Landsburg,
J. Svoboda,
S. Nasta,
J. Gerson,
S. Barta,
E. Chong,
S. Schuster,
I. Paydar,
A. Maity,
J. Plastaras
|
6 |
2020 |
6 π
|
π
|
Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease
10 auth.
A. Cohen,
S. Luger,
C. Sickles,
P. Mangan,
D. Porter,
S. Schuster,
...
D. Tsai,
S. Nasta,
A. Gewirtz,
E. Stadtmauer
|
6 |
2002 |
6 π
|
π¦
|
Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial of Tisagenlecleucel
28 auth.
S. Schuster,
Michael R. Bishop,
C. Tam,
P. Borchmann,
U. Jaeger,
Edmund K. Waller,
H. Holte,
J. Mcguirk,
S. Jaglowski,
K. Tobinai,
C. Andreadis,
I. Fleury,
S. Mielke,
T. Teshima,
J. Westin,
...
V. Bachanova,
S. R. Foley,
P. J. Ho,
J. Magenau,
N. Wagner-Johnston,
Koji Kato,
M. Kersten,
K. van Besien,
J. Chu,
Aline Jary,
Γ. Anak,
G. Salles,
R. Maziarz
|
5 |
2018 |
5 π¦
|
π’
|
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update
40 auth.
M. Dreyling,
Nathan H. Fowler,
Michael Dickinson,
J. MartΓnez-LΓ³pez,
Arne Kolstad,
Jason Butler,
M. Ghosh,
L. Popplewell,
J. Chavez,
E. Bachy,
Koji Kato,
H. Harigae,
M. J. Kersten,
C. Andreadis,
P. Riedell,
...
P. J. Ho,
J. PΓ©rez-SimΓ³n,
Andy Chen,
L. Nastoupil,
B. von Tresckow,
A. Ferreri,
Takanori Teshima,
Piers E. M. Patten,
Jospeh P McGuirk,
A. Petzer,
F. Offner,
A. Viardot,
P. Zinzani,
Ram Malladi,
I. Paule,
Aiesha Zia,
R. Awasthi,
Xia Han,
David Germano,
Darragh O'Donovan,
R. Ramos,
H. Maier,
Aisha Masood,
C. Thieblemont,
S. Schuster
|
4 |
2024 |
4 π’
|
π¦
|
Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas
17 auth.
S. Schuster,
Ling-Yuh Huw,
C. Bolen,
Victor Maximov,
A. Polson,
Katerina Hatzi,
E. A. Lasater,
S. Assouline,
N. L. Bartlett,
L. Budde,
...
Matthew J. Matasar,
Hartmut Koeppen,
E. Piccione,
D. Wilson,
Michael C Wei,
S. Yin,
E. Penuel
|
4 |
2023 |
4 π¦
|
π
|
Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagenlecleucel
30 auth.
C. Andreadis,
C. Tam,
P. Borchmann,
U. Jaeger,
J. Mcguirk,
H. Holte,
Edmund K. Waller,
S. Jaglowski,
Michael R. Bishop,
S. R. Foley,
J. Westin,
I. Fleury,
P. Ho,
S. Mielke,
T. Teshima,
...
G. Salles,
S. Schuster,
V. Bachanova,
R. Maziarz,
K. van Besien,
K. Izutsu,
J. Magenau,
N. Wagner-Johnston,
Koji Kato,
P. Corradini,
R. Tiwari,
R. Awasthi,
T. Lawniczek,
L. Eldjerou,
M. Kersten
|
4 |
2019 |
4 π
|